Press Releases

Date Title and Summary
Toggle Summary Isis Announces Positive Decision on European Orphan Drug Designation for ISIS-APOCIII Rx
Toggle Summary Isis Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Toggle Summary Isis Pharmaceuticals to Present at the Oppenheimer 24th Annual Healthcare Conference
Toggle Summary Isis Pharmaceuticals Earns $2 Million from GSK for the Advancement of ISIS-TTR Rx
Toggle Summary Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-GSK3 Rx and Earns $3 Million Milestone Payment From GSK
Toggle Summary Isis Pharmaceuticals to Present at the 2013 Deutsche Bank BioFEST
Toggle Summary Isis Pharmaceuticals to Investigate a Higher Dose of ISIS-SMN Rx in Children with Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals Reports Fifth Positive Phase 2 Data Set for ISIS-APOCIII Rx Showing Significant Reductions in Triglyceride and ApoC-III Levels
Toggle Summary Isis Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-APO(a) Rx Produces Significant Reductions in Lp(a) Levels
Toggle Summary Isis Earns $5 Million in Milestone Payment from GSK for Advancement of ISIS-GSK4 Rx
Toggle Summary Isis Pharmaceuticals Earns $1.5M from the Advancement of the Phase 2 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
Toggle Summary Isis Reports Financial Results and Highlights for Third Quarter 2013
Toggle Summary Webcast Alert: Isis Pharmaceuticals' Third Quarter 2013 Financial Results Conference Call
Toggle Summary Isis Earns $10 Million Milestone Payment from Biogen Idec for Advancement of ISIS-DMPK Rx to Treat Myotonic Dystrophy
Toggle Summary Isis Pharmaceuticals' Stanley Crooke Awarded 2013 Distinguished Scientist
Toggle Summary Isis Earns $7 Million in Milestone Payments from GSK for Advancement of ISIS-GSK3 Rx to Treat Viral Infection
Toggle Summary Isis Pharmaceuticals Advances Phase 2 Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals to Present at the Leerink Swann Rare Disease Roundtable
Toggle Summary Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Substantial Reductions of Triglycerides and Apoc-III in Patients With Familial Chylomicronemia
Toggle Summary Isis Reports Follow-Up Data From ISIS-SMN Rx Phase 1 Study in Children With Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals' Stanley Crooke Awarded Corporate Forum's Director of the Year
Toggle Summary Biogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders
Toggle Summary Isis Pharmaceuticals to Present at the 2013 Stifel Healthcare Conference
Toggle Summary Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
Toggle Summary Isis Reports Interim Phase 2 Data on ISIS-APOCIII Rx as a Single Agent in Patients With Very High to Severely High Triglycerides
Toggle Summary Isis Pharmaceuticals to Present at the Canaccord Genuity 33rd Annual Growth Conference
Toggle Summary Isis Reports Financial Results and Highlights for Second Quarter 2013
Toggle Summary Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients With Rheumatoid Arthritis
Toggle Summary Isis Pharmaceuticals Earns $2 Million From GSK for the Advancement of ISIS-TTR Rx
Toggle Summary Webcast Alert: Isis Pharmaceuticals' Second Quarter 2013 Financial Results Conference Call
Toggle Summary Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Significant Reductions of ApoC-III and Triglycerides in Patients With High Triglycerides Taking Fibrates
Toggle Summary Isis Pharmaceuticals to Present at the 8th Annual JMP Securities Healthcare Conference
Toggle Summary Breaux Castleman Joins Isis Pharmaceuticals' Board of Directors
Toggle Summary Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Significant Reductions in Triglycerides and APOC-III in Patients With High Triglycerides and Type 2 Diabetes
Toggle Summary Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House
Toggle Summary Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology Studies
Toggle Summary Isis Pharmaceuticals Earns $6 Million Payment from AstraZeneca
Toggle Summary Isis Pharmaceuticals to Present at the Goldman Sachs 34th Annual Global Healthcare Conference
Toggle Summary Isis Pharmaceuticals Reports Encouraging Data on ISIS-STAT3rx in Patients With Cancer
Toggle Summary Isis Pharmaceuticals Earns $10 Million Milestone Payment from AstraZeneca For ISIS-AR Rx to Treat Prostate Cancer
Toggle Summary Isis Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares
Toggle Summary Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference
Toggle Summary Isis Pharmaceuticals to Present at the 2013 UBS Global Healthcare Conference
Toggle Summary Isis Pharmaceuticals Earns $3.5 Million From Biogen Idec
Toggle Summary Isis Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Toggle Summary Isis Pharmaceuticals Prices Public Offering Of Common Stock
Toggle Summary Isis Pharmaceuticals Announces Proposed Public Offering of Common Stock
Toggle Summary Isis Reports Financial Results and Highlights for First Quarter 2013
Toggle Summary Isis Pharmaceuticals Announces the Initiation of a Clinical Study of ISIS-STAT3 Rx in Patients With Liver Cancer
Toggle Summary Webcast Alert: Isis Pharmaceuticals' First Quarter 2013 Financial Results Conference Call
Toggle Summary ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference
Toggle Summary Roche and Isis Pharmaceuticals Form Alliance for Huntington's Disease
Toggle Summary Isis Initiates Phase 1 Study of ISIS-APOA Rx to Treat Atherosclerosis
Toggle Summary Isis Publishes Data Demonstrating Antisense Targeting of ApoC-III Significantly Reduces ApoC-III and Triglycerides
Toggle Summary Isis Provides Update on CHMP Opinion on KYNAMRO™ (mipomersen)
Toggle Summary Data From ISIS-SMN Rx Phase 1 Study in Children With Spinal Muscular Atrophy Presented at the American Academy of Neurology Meeting
Toggle Summary Isis Pharmaceuticals to Present at the 25th Annual ROTH Conference
Toggle Summary Isis Pharmaceuticals to Host Investor Event to Discuss ISIS-SMN Rx Data Presented at 2013 AAN Annual Meeting
Toggle Summary Isis Pharmaceuticals Reports Clinical Data Showing Blunting of Severe Increases in CRP Following Endotoxin Challenge With ISIS-CRP Rx
Toggle Summary Isis Pharmaceuticals to Present at the Barclays Global Healthcare Conference
Toggle Summary Isis Reports Financial Results and Highlights for 2012
Toggle Summary Isis Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
Toggle Summary Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-CRP Rx in Patients With Atrial Fibrillation
Toggle Summary Webcast Alert: Isis Pharmaceuticals' 2012 Financial Results and Highlights Conference Call
Toggle Summary Isis Initiates Phase 2/3 Study of ISIS-TTR Rx and Earns $7.5 Million Milestone Payment From GlaxoSmithKline
Toggle Summary Isis Pharmaceuticals to Present at the 2013 Leerink Swann Global Healthcare Conference
Toggle Summary Isis Pharmaceuticals to Provide Update on FDA Approval of KYNAMRO™ (mipomersen)
Toggle Summary Genzyme and Isis Announce FDA Approval of KYNAMRO™ (mipomersen sodium) Injection for the Treatment of Homozygous Familial Hypercholesterolemia
Toggle Summary Isis Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference
Toggle Summary Isis Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference
Toggle Summary Genzyme and Isis Provide Update on CHMP Opinion on KYNAMRO™ (mipomersen)
Toggle Summary Isis Pharmaceuticals To Review CHMP Opinion On KYNAMRO™
Toggle Summary Isis Announces That ISIS-TTR Rx Was Granted Fast Track Designation For The Treatment Of Patients With FAP
Toggle Summary Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
Toggle Summary Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
Toggle Summary Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
Toggle Summary Isis Pharmaceuticals To Provide Update On Its Metabolic Franchise
Toggle Summary Isis Pharmaceuticals To Present At The 24th Annual Piper Jaffray Healthcare Conference
Toggle Summary Isis Pharmaceuticals To Present At The 2012 Credit Suisse Healthcare Conference
Toggle Summary Isis Pharmaceuticals To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
Toggle Summary Isis Reports Financial Results and Highlights for Third Quarter 2012
Toggle Summary Isis Announces Expedited Development Of ISIS-TTR Rx And Amendment To The Collaboration With GSK To Support Phase 2/3 Study
Toggle Summary Isis To Receive $1.25 Million Payment As Pfizer Continues Development Of EXC 001
Toggle Summary Isis Pharmaceuticals Initiates Phase 1b/2a Study Of ISIS-SMNRx In Patients With Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals Reports Encouraging Interim Phase 1 Data On ISIS-STAT3Rx In Patients With Cancer
Toggle Summary Isis Initiates Phase 2 Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery
Toggle Summary Webcast Alert: Isis Pharmaceuticals' Third Quarter 2012 Financial Results Conference Call
Toggle Summary Isis Pharmaceuticals To Receive $1.1 Million From Alnylam
Toggle Summary FDA Advisory Committee Recommends KYNAMRO™ for Homozygous Familial Hypercholesterolemia
Toggle Summary ISIS Pharmaceuticals Stock Trading Halted Today
Toggle Summary Isis Investment In Regulus Valued At $28 Million At Completion Of Regulus Initial Public Offering
Toggle Summary Regulus Announces Pricing of Initial Public Offering
Toggle Summary Isis Pharmaceuticals Completes Redemption Of 2 5/8% Convertible Subordinated Notes Due 2027
Toggle Summary Isis Pharmaceuticals To Present At The UBS Global Life Sciences Conference
Toggle Summary Isis Pharmaceuticals To Present At Two Upcoming Investor Conferences
Toggle Summary Isis Pharmaceuticals Demonstrates The Potential Of Single-Stranded RNA-Like Antisense Technology To Activate The RNAi Pathway
Toggle Summary Isis Pharmaceuticals to Present at the 2012 Stifel Nicolaus Healthcare Conference
Toggle Summary Isis Pharmaceuticals to receive $1.4 million from Alnylam
Toggle Summary Webcast Alert: Isis Pharmaceuticals Hosts Dr. Klaus Parhofer to Review KYNAMRO™ Data Presented at the European Society of Cardiology Congress 2012
©1999 - 2017 Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc.